MabVax Therapeutics Selected To Present at 2015 BIO CEO & Investor Conference
SAN DIEGO, Feb. 4, 2015 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a cancer diagnostic and immunotherapy company, announced today that it has been selected to make a corporate presentation in the public company program at the upcoming BIO CEO & Investor Conference at 1:00 pm E.T. on Tuesday, February 10th in New York City.
MabVax's CEO David Hansen will present a corporate update including highlighting the significant progress made in the last year and plans for continuing development of its lead antibody candidate HuMab 5B1 as a diagnostic product and therapeutic agent in the diagnosis and treatment of GI cancers and specifically pancreatic cancer. The antibody product is scheduled to enter Phase I clinical trials latter this year. Mr. Hansen will also update investors and interested corporate entities on the therapeutic cancer vaccine program, which has two products in late stage Phase II clinical trials. He will discuss the upcoming Phase II trial in the childhood cancer neuroblastoma for which MabVax's therapeutic vaccine candidate received an Orphan Drug Designation from FDA in September 2014.
About HuMab 5B1
Recently MabVax nominated its HuMab 5B1 antibody as a clinical candidate for the diagnosis and treatment of pancreatic and colon cancer. The fully human antibody, recovered from one of the patients undergoing cancer vaccine treatment at Memorial Sloan-Kettering Cancer Center, has entered GMP manufacturing to produce clinical trial supplies for a planned Phase 1 program to begin in the second half of 2015. The development plan calls for dual Phase 1 clinical trials. One program will be aimed at demonstrating the utility of the radiolabeled antibody as a next generation PET imaging agent for the diagnosis and management of pancreatic cancer. The second program will determine the safety and potential utility of the full-length antibody as a treatment for the same cancer.
About MabVax
MabVax Therapeutics Holdings, Inc. is cancer diagnostic and immunotherapy company focused on the development of vaccine and antibody based therapies to address unmet medical needs in the treatment of cancer. MabVax has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers with the Company's proprietary vaccines. MabVax has the exclusive license to the therapeutic vaccines from Memorial Sloan Kettering Cancer Center. MabVax has two cancer vaccines targeting recurrent sarcoma and ovarian cancer in proof of concept Phase II multi-center clinical trials, and a vaccine targeting neuroblastoma ready for Phase II clinical development.
Additional information about the Company is available at www.mabvax.com.
Forward Looking Statements
This press release contains "forward-looking statements" regarding matters that are not historical facts, including statements relating to the Company's development pipeline. We are unable to provide assurance that all of the product development candidates in the pipeline will be fully developed by the Company. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "anticipates," "plans," "expects," "intends," "will," "potential," "hope" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its annual report on Form 10-K for the fiscal year ended December 31, 2013 and in the Proxy Statement dated July 25, 2014, as amended and supplemented in our quarterly report on Form 10-Q for September 30, 2014. The parties do not undertake any obligation to update forward-looking statements contained in this press release.
SOURCE MabVax Therapeutics Holdings, Inc.
Share this article